https://sms.carm.es/ricsmur/handle/123456789/17188 2026-04-15T07:03:24Z 2026-04-15T07:03:24Z Martínez, Elena Fernández-Villacañas, Miguel-Ángel Moreno, María-Matilde Flores-Funes, Diego https://sms.carm.es/ricsmur/handle/123456789/25389 2026-03-10T12:10:27Z 2025-01-28T00:00:00Z

Drawing as a learning tool for anatomy: design and implementation of a method Martínez, Elena; Fernández-Villacañas, Miguel-Ángel; Moreno, María-Matilde; Flores-Funes, Diego

2025-01-28T00:00:00Z Perez-Sanz, Fernando; Tyrkalska, Sylwia D.; Alvarez-Santacruz, Carmen; Moreno-Docon, Antonio; Mulero, Victoriano; Cayuela, Maria L.; Candel, Sergio https://sms.carm.es/ricsmur/handle/123456789/25320 2026-03-10T12:03:24Z 2025-03-01T00:00:00Z

Age- and disease severity-associated changes in the nasopharyngeal microbiota of COVID-19 patients Perez-Sanz, Fernando; Tyrkalska, Sylwia D.; Alvarez-Santacruz, Carmen; Moreno-Docon, Antonio; Mulero, Victoriano; Cayuela, Maria L.; Candel, Sergio Although many studies have associated changes in the nasopharyngeal microbiota to patient's susceptibility to COVID-19, their results are highly variable and contradictory. Addressing the limitations in previous research responsible for that variability, this study uses 16S rRNA gene sequencing to analyze the nasopharyngeal microbiota of 395 subjects, 117 controls, and 278 COVID-19 patients, of different age groups that cover the entire lifespan and across varying disease severities. This revealed that bacterial alpha diversity decreases progressively throughout life but only in severely ill COVID-19 patients, in whose nasopharynx, moreover, several opportunistic pathogen bacterial genera are overrepresented. Notably, Scardovia wiggsiae appears only in severe COVID-19 patients over 60 years of age, suggesting its potential utility as a COVID-19 severity biomarker in the elderly, who are the most susceptible individuals to suffer from serious forms of the disease. Thus, our results provide valuable insights into age-associated dynamics within nasopharyngeal microbiota during severe COVID-19.

2025-03-01T00:00:00Z Facila, Lorenzo Cordero, Alberto Valverde-Tavira, Adrián Rilo-Miranda, Irene Laskibar-Asua, Alain Tirapu, Laia Montagud, Vicente Sánchez-Serna, Juan Gómez-Mariscal, Eloy Mainar, Luis Martín-Dorado, Ernesto Lorenzo, Natalia Pello-Lazaro, Ana-María Rodríguez-Manero, Moises https://sms.carm.es/ricsmur/handle/123456789/25318 2026-03-10T12:03:23Z 2025-04-01T00:00:00Z

Characterization and anticoagulation treatment patterns of hospitalized patients with nonvalvular atrial fibrillation in Spain: The CARISMA registry Facila, Lorenzo; Cordero, Alberto; Valverde-Tavira, Adrián; Rilo-Miranda, Irene; Laskibar-Asua, Alain; Tirapu, Laia; Montagud, Vicente; Sánchez-Serna, Juan; Gómez-Mariscal, Eloy; Mainar, Luis; Martín-Dorado, Ernesto; Lorenzo, Natalia; Pello-Lazaro, Ana-María; Rodríguez-Manero, Moises BACKGROUND: This study described the clinical and demographic characteristics of hospitalized patients with nonvalvular atrial fibrillation (NVAF) and prescriptions for vitamin-K antagonists (VKA) and direct-acting oral anticoagulants (DOAC) in Spain. METHODS: This was an observational, multicentric, retrospective study of patients treated with DOAC or VKA due to NVAF at cardiology services of hospitals in Spain. A registry (CARISMA) included patients hospitalized for any reason and discharged before July 1st, 2021, with a prescription for DOAC or VKA. Data was collected on demographic and clinical characteristics and anticoagulant treatments prescribed. Analyses were descriptive. RESULTS: A total of 1,041 patients were included. Mean age (SD) was 77.2 (10.3) years and 57.6 % were men. The most frequent reason for hospital admission was heart failure (43.8 %) and arrhythmias (25.0 %). The mean (SD) CHA(2)DS(2)-VASc score was 4.0 (1.6). Prior to admission, 75.6 % of patients had been prescribed anticoagulant treatment for NVAF. Of these, 56.0 % had received VKA and 44.0 % DOAC. At discharge, 60 % had a DOAC prescription (of these, apixaban, 37.6 %; edoxaban, 26.4 %; rivaroxaban, 25.1 %; dabigatran, 10.9 %) and 40 % a VKA. DOAC prescriptions were off-label with respect to dosing in 19-34 % of cases. Patients with off-label dosing were older and with a higher proportion of women than those with on-label doses. During hospitalization, 12.1 % of patients changed treatment, usually VKA to DOAC. CONCLUSION: Before hospitalization, a quarter of patients with NVAF were not receiving anticoagulation medication. Hospitalization increased the proportion of patients receiving DOAC, but about a quarter of patients had off-label dosing prescriptions.

2025-04-01T00:00:00Z Ruiz-Lorente, Inmaculada; Gimeno, Lourdes; Lopez-Abad, Alicia; Cubillana, Pedro Lopez; Aparicio, Tomas Fernandez; Egea, Lucas Jesus Asensio; Aviles, Juan Moreno; Iniguez, Gloria Donate; Martinez-Valls, Pablo Luis Guzman; Server, Gerardo; Ferri, Belen; Campillo, Jose Antonio; Galindo, Francisco; Martinez-Sanchez, Maria Victoria; Minguela, Alfredo https://sms.carm.es/ricsmur/handle/123456789/25266 2026-03-10T12:10:29Z 2025-12-31T00:00:00Z

HLA class-I genotyping to personalize Bacille Calmette-Guerin immunotherapy in bladder cancer Ruiz-Lorente, Inmaculada; Gimeno, Lourdes; Lopez-Abad, Alicia; Cubillana, Pedro Lopez; Aparicio, Tomas Fernandez; Egea, Lucas Jesus Asensio; Aviles, Juan Moreno; Iniguez, Gloria Donate; Martinez-Valls, Pablo Luis Guzman; Server, Gerardo; Ferri, Belen; Campillo, Jose Antonio; Galindo, Francisco; Martinez-Sanchez, Maria Victoria; Minguela, Alfredo Bacille Calmette-Guerin (BCG) is the immunotherapy of choice for high-risk non-muscle invasive bladder cancer (BC), although recurrence eventually occurs in 50% of patients and 20% progress to advanced stages. This study evaluates the predictive value of human leukocyte antigen class-I (HLA-I) genotyping to guide BCG immunotherapy. HLA-I genotyping and expression of NK cell receptors in circulating T and NK lymphocytes was evaluated at diagnosis in 325 consecutive BC patients (151 treated with BCG and 174 with other therapies), 648 patients with other cancers and 23,250 healthy controls. Proliferation, cytotoxicity, and production of cytokines and intracellular nitric oxide (icNO) was assessed in peripheral blood mononuclear cells from these donors, selected based on their Bw4 genotype, after stimulation in vitro with anti-CD3/CD28 or BCG. HLA-A11, HLA-B07 and HLA-B18 allotypes were associated with favorable outcomes after BCG therapy (longer progression-free and overall survival), whereas HLA-B44 and other KIR3DL1 Bw4 ligands were associated with unfavorable outcomes. Although Bw4 ligands were associated with better NK cell education in vivo (CD226-upregulation, KIR3DL1 downregulation and stronger NK cytotoxic capacity), they were also associated with weaker NK cell proliferation, and lower IL-1?, IL-6, and icNO production after BCG stimulation in vitro, revealing an inhibitory role of KIR3DL1. Mechanisms by which KIR3DL1/Bw4 interaction interferes with BCG-induced NK cell proliferation and the production of cytokines and icNO, warrant further investigation. HLA-I genotyping should be investigated as a useful biomarker to personalize BCG immunotherapy in BC.

2025-12-31T00:00:00Z